NIH Clinical Trial Integrity Act
The NIH Clinical Trial Integrity Act would direct the Department of Health and Human Services, acting through NIH, to require more detailed diversity planning for NIH-funded clinical trials of drugs, devices, biologics, and certain behavioral interventions. Applicants would have to submit measurable recruitment and retention goals, explain how those goals reflect the race, ethnicity, age, and sex of the relevant patient population or the general population when disease prevalence is unknown, and provide a plan for analyzing demographic groups separately and enrolling enough participants to produce statistically meaningful results. The bill also allows applicants to explain why recruiting certain groups is not scientifically justified or possible.
The bill further requires NIH-funded trial sponsors to report demographic enrollment and retention data during the trial, complete diversity-related training, and submit final participant counts by race, ethnicity, age, and sex, while protecting privacy and prohibiting disclosure of identifiable or protected health information. It also directs NIH to study ways to reduce cost barriers for participants, including reimbursement of out-of-pocket expenses, compensation for time, recruitment incentives, and possible changes to anti-kickback safe harbor rules. In addition, it creates a national public awareness campaign and grant program to support outreach, education, and recruitment efforts through nonprofits, community organizations, faith communities, colleges, and community pharmacies.
If enacted, the bill would add new federal conditions on NIH funding and NIH protocol approval for clinical trials, effectively changing how NIH-funded researchers design, justify, monitor, and report participant recruitment and retention. It would also require NIH to conduct a study on regulatory changes related to participant reimbursement and incentives, and to launch a nationwide education and outreach effort with grant funding of $10 million annually from fiscal years 2026 through 2029. The bill would not directly amend the Food, Drug, and Cosmetic Act or the Public Health Service Act, but it would operate through NIH funding rules and related HHS/NIH administrative requirements, affecting researchers, sponsors, universities, hospitals, community organizations, and trial participants.
The available context shows no committee transcript and no recorded votes, so there is no documented floor or committee debate to gauge partisan or stakeholder sentiment. Based on the bill text, the measure appears to be framed positively around improving clinical trial representation, reducing barriers to participation, and increasing public awareness. The sponsors’ introduction suggests support for the goal of more inclusive and scientifically representative research, but the absence of voting history or hearing testimony means broader legislative sentiment cannot be assessed from the provided materials.
The main potential points of contention are likely to be the added administrative and reporting burdens on NIH-funded researchers and sponsors, the feasibility of meeting demographic recruitment targets, and the bill’s requirement to justify why certain populations are not included. Another possible issue is the study of reimbursement, compensation, and recruitment incentives, including whether changes to anti-kickback safe harbor rules could create compliance concerns or unintended consequences. Supporters would likely emphasize equity, better data, and improved trial validity, while critics may focus on cost, regulatory complexity, and whether rigid diversity requirements could interfere with scientific design in some studies.